

Psalmotoxin 1

Cat. No.:	HY-P1411
CAS No.:	880107-52-8
Molecular Formula:	C ₂₀₀ H ₃₁₂ N ₆₂ O ₅₇ S ₆
Molecular Weight:	4689.41
Sequence:	Glu-Asp-Cys-Ile-Pro-Lys-Trp-Lys-Gly-Cys-Val-Asn-Arg-His-Gly-Asp-Cys-Cys-Glu-Gly-Leu-Glu-Cys-Trp-Lys-Arg-Arg-Arg-Ser-Phe-Glu-Val-Cys-Val-Pro-Lys-Thr-Pro-Lys-Thr (Disulfide bridge: Cys3-Cys18, Cys10-Cys23, Cys17-Cys33)
Sequence Shortening:	EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCPKTPKT (Disulfide bridge: Cys3-Cys18, Cys10-Cys23, Cys17-Cys33)
Target:	Sodium Channel; Apoptosis
Pathway:	Membrane Transporter/Ion Channel; Apoptosis
Storage:	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

BIOLOGICAL ACTIVITY

Description	Psalmotoxin 1 (PcTx1) is a protein toxin that can bind at subunit-subunit interfaces of acid-sensing ion channel 1a (ASIC1a). Psalmotoxin 1 is a potent and selective ASIC1a inhibitor (IC ₅₀ : 0.9 nM) by increasing the apparent affinity for H ⁺ of ASIC1a. Psalmotoxin 1 can induce cell apoptosis, also inhibits cell migration, proliferation and invasion of cancer cells. Psalmotoxin 1 can be used in the research of cancers, or neurological disease ^{[1][3][4][6]} .								
IC₅₀ & Target	IC ₅₀ : 0.9 nM (ASIC1a), 50 nM (ASIC1b, ASIC2a, and ASIC3) ^[6] .								
In Vitro	<p>Psalmotoxin 1 (20 nM, 125 s) inhibits ASIC1a currents by drastically shifting the steady-state desensitization curve to lower H⁺ concentrations^[1].</p> <p>Psalmotoxin 1 (30 nM) competes with Ca²⁺ in binding to ASIC1a channels^[1].</p> <p>Psalmotoxin 1 (100 or 200 ng, 24-72 h) significantly weakens the migration, proliferation and invasion of MCF-7 and MDA-MB-231 cells^[4].</p> <p>Psalmotoxin 1 (100 ng/mL, 24 h) significantly inhibits acid-induced increases in intracellular calcium and LDH release, induces cell apoptosis and cell cycle arrest in nucleus pulposus cells (NPCs)^[5].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[4]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 and MDA-MB-231 cells</td> </tr> <tr> <td>Concentration:</td> <td>100 or 200 ng</td> </tr> <tr> <td>Incubation Time:</td> <td>24, 48, 72 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited the cell migration, proliferation and invasion of breast cancer cells.</td> </tr> </table> <p>Western Blot Analysis^[5]</p>	Cell Line:	MCF-7 and MDA-MB-231 cells	Concentration:	100 or 200 ng	Incubation Time:	24, 48, 72 h	Result:	Inhibited the cell migration, proliferation and invasion of breast cancer cells.
Cell Line:	MCF-7 and MDA-MB-231 cells								
Concentration:	100 or 200 ng								
Incubation Time:	24, 48, 72 h								
Result:	Inhibited the cell migration, proliferation and invasion of breast cancer cells.								

	Cell Line:	Nucleus pulposus cells (NPCs)
	Concentration:	100 ng/mL
	Incubation Time:	24 h
	Result:	Decreased Bax and cleaved caspase-3 expression, and increased Bcl-2 expression.
In Vivo	<p>Psalmotoxin 1 (i.c.v., 1 ng/kg, a single dose) is neuroprotective in a conscious model of stroke via direct inhibition of ASIC1a [2].</p> <p>Psalmotoxin 1 (tail vein injection, 10 ng/kg, daily for 7 days) inhibits tumor growth in breast cancer mice model^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	Male spontaneously hypertensive rats (SHR) ^[2]
	Dosage:	1 ng/kg, a single dose.
	Administration:	Intracerebroventricular (i.c.v.) injection
	Result:	<p>Reduced cortical and striatal infarct volumes measured 72 h post-stroke.</p> <p>Reduced the severity of motor deficit at 1 and 3 days after stroke compared to control rats.</p> <p>Displayed an anti-apoptotic effect in the occluded hemisphere (reduced stroke-induced caspase-3 positive cells).</p>
	Animal Model:	Female nude BALB/C mice (orthotopic implantation, MCF-7 and MDA-MB-231 cells) ^[3]
	Dosage:	10 ng/kg, daily for 7 days.
	Administration:	Tail vein injection
	Result:	Inhibited breast tumor growth.

CUSTOMER VALIDATION

- Aging. 2021 Apr 6;13(7):10703-10723.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Claudia A McCarthy, et al. PcTx1 affords neuroprotection in a conscious model of stroke in hypertensive rats via selective inhibition of ASIC1a. *Neuropharmacology*. 2015 Dec;99:650-7.
- [2]. Niko Joeres, et al. Functional and pharmacological characterization of two different ASIC1a/2a heteromers reveals their sensitivity to the spider toxin PcTx1. *Sci Rep*. 2016 Jun 9;6:27647. doi: 10.1038/srep27647.
- [3]. Chao Yang, et al. Overexpression of acid-sensing ion channel 1a (ASIC1a) promotes breast cancer cell proliferation, migration and invasion. *Transl Cancer Res*. 2020 Dec;9(12):7519-7530.
- [4]. Feng Cai, et al. Acid-sensing ion channel 1a regulates the survival of nucleus pulposus cells in the acidic environment of degenerated intervertebral discs. *Iran J Basic Med Sci*. 2016 Aug;19(8):812-820.

[5]. P Escoubas, et al. Isolation of a tarantula toxin specific for a class of proton-gated Na⁺ channels. J Biol Chem. 2000 Aug 18;275(33):25116-21.

[6]. Chen X, et al. The tarantula toxin psalmotoxin 1 inhibits acid-sensing ion channel (ASIC) 1a by increasing its apparent H⁺ affinity. J Gen Physiol. 2005 Jul;126(1):71-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA